Managing the challenge of chemically reactive metabolites in drug development

Nature Reviews Drug Discovery

Volumn 10, Issue 4, 2011, Pages 292-306

  Park, B Kevin ^a   Boobis, Alan ^b   Clarke, Stephen ^c   Goldring, Chris E P ^a   Jones, David ^d   Kenna, J Gerry ^e   Lambert, Craig ^e   Laverty, Hugh G ^a   Naisbitt, Dean J ^a   Nelson, Sidney ^f   Nicoll Griffith, Deborah A ^g   Obach, R Scott ^h   Routledge, Philip ⁱ   Smith, Dennis A ^j   Tweedie, Donald J ^k   Vermeulen, Nico ^l   Williams, Dominic P ^a   Wilson, Ian D ^e   Baillie, Thomas A ^f  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f UNIVERSITY OF WASHINGTON   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h PFIZER INC   (United States)

ⁱ CARDIFF UNIVERSITY   (United Kingdom)

^j PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^k BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^l VU UNIVERSITY AMSTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ARTEMISININ; BETA LACTAM ANTIBIOTIC; BICALUTAMIDE; CHEMICALLY REACTIVE METABOLITE; DICLOFENAC; DRUG METABOLITE; FLUTAMIDE; HALOTHANE; KETOPROFEN; MELOXICAM; NILUTAMIDE; NITRILE; NONSTEROID ANTIINFLAMMATORY AGENT; SUDOXICAM; SULFAMETHOXAZOLE; SUPROFEN; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

DRUG ACTIVITY; DRUG CONTROL; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; RISK ASSESSMENT;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 79953314978     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3408     Document Type: Review

References (89)

1. Lasser, K. E. et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287, 2215-2220 (2002). (Pubitemid 34441937)
2. Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947-954 (2002). (Pubitemid 35440240)
3. Adams, D. H., Ju, C., Ramaiah, S. K., Uetrecht, J. & Jaeschke, H. Mechanisms of immune-mediated liver injury. Toxicol. Sci. 115, 307-321 (2010).
4. Li, J. & Uetrecht, J. P. The danger hypothesis applied to idiosyncratic drug reactions. Handb. Exp. Pharmacol. 196, 493-509 (2010).
5. Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M. & Williams, D. P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45, 177-202 (2005). (Pubitemid 40261802)
6. Erve, J. C. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. Expert Opin. Drug Metab. Toxicol. 2, 923-946 (2006). (Pubitemid 44911540)
7. Guengerich, F. P. & MacDonald, J. S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20, 344-369 (2007). (Pubitemid 46548682)
8. Kalgutkar, A. S. & Soglia, J. R. Minimising the potential for metabolic activation in drug discovery. Expert Opin. Drug Metab. Toxicol. 1, 91-142 (2005).
9. Nelson, S. D. Structure toxicity relationships - how useful are they in predicting toxicities of new drugs? Adv. Exp. Med. Biol. 500, 33-43 (2001). (Pubitemid 34106976)
10. Walgren, J. L., Mitchell, M. D. & Thompson, D. C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35, 325-361 (2005). (Pubitemid 40691298)
11. Tirmenstein, M. A. & Nelson, S. D. Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3′-hydroxyacetanilide, in mouse liver. J. Biol. Chem. 264, 9814-9819 (1989). (Pubitemid 19159244)
12. Liebler, D. C. Protein damage by reactive electrophiles: targets and consequences. Chem. Res. Toxicol. 21, 117-128 (2008). (Pubitemid 351219713)
13. Kenna, J. G. in Drug Induced Liver Disease (eds Kaplowitz, N., & DeLeve, L. D.) 465-484 (Marcel Dekker, New York, 2007).
14. Obach, R. S., Kalgutkar, A. S., Soglia, J. R. & Zhao, S. X. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 21, 1814-1822 (2008).
15. Coles, B. et al. The spontaneous and enzymatic reaction of N-acetyl-p-benzoquinonimine with glutathione: a stopped-flow kinetic study. Arch. Biochem. Biophys. 264, 253-260 (1988).
16. Tingle, M. D., Mahmud, R., Maggs, J. L., Pirmohamed, M. & Park, B. K. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. J. Pharmacol. Exp. Ther. 283, 817-823 (1997). (Pubitemid 27514644)
17. Nakayama, S. et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 37, 1970-1977 (2009).
18. Usui, T., Mise, M., Hashizume, T., Yabuki, M. & Komuro, S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos. 37, 2383-2392 (2009).
19. de Rooij, B. M., Boogaard, P. J., Commandeur, J. N., van Sittert, N. J. & Vermeulen, N. P. Allylmercapturic acid as urinary biomarker of human exposure to allyl chloride. Occup. Environ. Med. 54, 653-661 (1997). (Pubitemid 27402238)
20. Nelson, E. B. The pharmacology and toxicology of meta-substituted acetanilide I: acute toxicity of 3-hydroxyacetanilide in mice. Res. Commun. Chem. Pathol. Pharmacol. 28, 447-456 (1980). (Pubitemid 10072425)
21. Bauman, J. N. et al. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol. 22, 332-340 (2009).
22. Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002). (Pubitemid 34215071)
23. Chessman, D. et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28, 822-832 (2008). (Pubitemid 351784513)
24. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A. & Baillie, T. A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16 (2004). (Pubitemid 38134055)
25. Smith, D. A. & Obach, R. S. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22, 267-279 (2009).
26. Smith, D. A., Obach, R. S., Williams, D. P. & Park, B. K. Clearing the MIST (metabolites in safety testing) of time: the impact of duration of administration on drug metabolite toxicity. Chem. Biol. Interact. 179, 60-67 (2009).
27. Kalgutkar, A. S. et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6, 161-225 (2005). (Pubitemid 40753853)
28. Uetrecht, J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov. Devel. 4, 55-59 (2001). (Pubitemid 32118459)
29. Day, S. H. et al. A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J. Pharmacol. Toxicol. Methods 52, 278-285 (2005). (Pubitemid 41207205)
30. Baillie, T. A. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol. 21, 129-137 (2008). (Pubitemid 351219714)
31. Bateman, K. P. et al. MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun. Mass Spectrom. 21, 1485-1496 (2007). (Pubitemid 46761970)
32. Fontana, E., Dansette, P. M. & Poli, S. M. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr. Drug Metab. 6, 413-454 (2005). (Pubitemid 41300789)
33. Kalgutkar, A. S., Obach, R. S. & Maurer, T. S. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab. 8, 407-447 (2007). (Pubitemid 47603408)
34. Danciu, T. E. & Whitman, M. Oxidative stress drives disulfide bond formation between basic helix-loop-helix transcription factors. J. Cell Biochem. 109, 417-424 (2010).
35. Jacobs, A. T. & Marnett, L. J. Heat shock factor 1 attenuates 4-hydroxynonenal-mediated apoptosis: critical role for heat shock protein 70 induction and stabilization of Bcl-XL. J. Biol. Chem. 282, 33412-33420 (2007). (Pubitemid 350159530)
36. Lieu, H. T. et al. Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice. Hepatology 44, 1452-1464 (2006).
37. Bateman, K. P. et al. Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem. Res. Toxicol. 17, 1356-1361 (2004). (Pubitemid 39391213)
38. Fang, J., Koen, Y. M. & Hanzlik, R. P. Bioinformatic analysis of xenobiotic reactive metabolite target proteins and their interacting partners. BMC Chem. Biol. 9, 5 (2009).
39. Hanzlik, R. P., Koen, Y. M., Theertham, B., Dong, Y. & Fang, J. The reactive metabolite target protein database (TPDB) - a web-accessible resource. BMC Bioinformatics 8, 95 (2007).
40. Gan, J., Harper, T. W., Hsueh, M. M., Qu, Q. & Humphreys, W. G. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18, 896-903 (2005). (Pubitemid 40705457)
41. Yan, Z., Maher, N., Torres, R. & Huebert, N. Use of a trapping agent for simultaneous capturing and high-throughput screening of both "soft" and "hard" reactive metabolites. Anal. Chem. 79, 4206-4214 (2007). (Pubitemid 46903174)
42. Ma, L., Wen, B., Ruan, Q. & Zhu, M. Rapid screening of glutathione-trapped reactive metabolites by linear ion trap mass spectrometry with isotope pattern-dependent scanning and postacquisition data mining. Chem. Res. Toxicol. 21, 1477-1483 (2008).
43. Ma, X. & Chan, E. C. Fluorescence-based liver microsomal assay for screening of pharmaceutical reactive metabolites using a glutathione conjugated 96-well plate. Bioconjug. Chem. 21, 46-55 (2010).
44. Fontana, R. J. et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl. Surg. 5, 480-484 (1999). (Pubitemid 29517862)
45. Hunter, E. B., Johnston, P. E., Tanner, G., Pinson, C. W. & Awad, J. A. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am. J. Gastroenterol. 94, 2299-2301 (1999). (Pubitemid 29374571)
46. Moses, P. L. et al. Severe hepatotoxicity associated with bromfenac sodium. Am. J. Gastroenterol. 94, 1393-1396 (1999). (Pubitemid 29214660)
47. Goldkind, L. & Laine, L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf. 15, 213-220 (2006).
48. Miyanaga, M. et al. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol. 87, 300-305 (2009).
49. Bakke, O. M., Manocchia, M., de Abajo, F., Kaitin, K. I. & Lasagna, L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin. Pharmacol. Ther. 58, 108-117 (1995).
50. Berson, A. et al. Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen. J. Pharmacol. Exp. Ther. 270, 167-176 (1994). (Pubitemid 24229625)
51. Wen, B. et al. Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH: cytochrome P450 reductase. Chem. Res. Toxicol. 21, 2393-2406 (2008).
52. Schellhammer, P. F. et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 50, 330-336 (1997). (Pubitemid 27428107)
53. Coe, K. J. et al. Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening. Chem. Res. Toxicol. 20, 1277-1290 (2007). (Pubitemid 47548296)
54. Bailey, M. J. & Dickinson, R. G. Acyl glucuronide reactivity in perspective: biological consequences. Chem. Biol. Interact. 145, 117-137 (2003). (Pubitemid 36398426)
55. Boelsterli, U. A. Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors. Int. J. Clin. Pract. 128, 30-36 (2002).
56. Boelsterli, U. A. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf. 25, 633-648 (2002).
57. Skonberg, C., Olsen, J., Madsen, K. G., Hansen, S. H. & Grillo, M. P. Metabolic activation of carboxylic acids. Expert Opin. Drug Metab. Toxicol. 4, 425-438 (2008). (Pubitemid 351728516)
58. Boelsterli, U. A. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr. Drug Metab. 3, 439-450 (2002). (Pubitemid 34778006)
59. Kitteringham, N. R. et al. Hepatocellular response to chemical stress in CD-1 mice: induction of early genes and γ-glutamylcysteine synthetase. Hepatology 32, 321-333 (2000). (Pubitemid 30614665)
60. Dambach, D. M., Durham, S. K., Laskin, J. D. & Laskin, D. L. Distinct roles of NF-κB p50 in the regulation of acetaminophen-induced inflammatory mediator production and hepatotoxicity. Toxicol. Appl. Pharmacol. 211, 157-165 (2006). (Pubitemid 43238309)
61. Xu, Z. et al. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc. Natl Acad. Sci. USA 102, 4120-4125 (2005). (Pubitemid 40388565)
62. Copple, I. M., Goldring, C. E., Kitteringham, N. R. & Park, B. K. The keap1-nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity. Handb. Exp. Pharmacol. 196, 233-266 (2010).
63. Chevillard, G., Nouhi, Z., Anna, D., Paquet, M. & Blank, V. Nrf3-deficient mice are not protected against acute lung and adipose tissue damages induced by butylated hydroxytoluene. FEBS Lett. 584, 923-928.
64. Cheng, J., Ma, X., Krausz, K. W., Idle, J. R. & Gonzalez, F. J. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab. Dispos. 37, 1611-1621 (2009).
65. Grosch, S., Fritz, G. & Kaina, B. Apurinic endonuclease (Ref-1) is induced in mammalian cells by oxidative stress and involved in clastogenic adaptation. Cancer Res. 58, 4410-4416 (1998). (Pubitemid 28450044)
66. Bykov, V. J., Lambert, J. M., Hainaut, P. & Wiman, K. G. Mutant p53 rescue and modulation of p53 redox state. Cell Cycle 8, 2509-2517 (2009).
67. Rzymski, T., Milani, M., Singleton, D. C. & Harris, A. L. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8, 3838-3847 (2009).
68. Pessler-Cohen, D. et al. GLUT4 repression in response to oxidative stress is associated with reciprocal alterations in C/EBP α and δ isoforms in 3T3-L1 adipocytes. Arch. Physiol. Biochem. 112, 3-12 (2006). (Pubitemid 43879109)
69. Stamper, B. D., Bammler, T. K., Beyer, R. P., Farin, F. M. & Nelson, S. D. Differential regulation of mitogen-activated protein kinase pathways by acetaminophen and its nonhepatotoxic regioisomer 3′-hydroxyacetanilide in TAMH cells. Toxicol. Sci. 116, 164-173 (2010).
70. McCubrey, J. A., Lahair, M. M. & Franklin, R. A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal. 8, 1775-1789 (2006). (Pubitemid 44726351)
71. Copple, I. M. et al. The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology 48, 1292-1301 (2008).
72. Dinkova-Kostova, A. T. et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl Acad. Sci. USA 99, 11908-11913 (2002). (Pubitemid 34994497)
73. Hong, F., Sekhar, K. R., Freeman, M. L. & Liebler, D. C. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J. Biol. Chem. 280, 31768-31775 (2005). (Pubitemid 41291926)
74. Itoh, K., Mimura, J. & Yamamoto, M. Discovery of the negative regulator of Nrf2, Keap1: A historical overview. Antioxid. Redox Signal. 13, 1665-1678 (2010).
75. Goldring, C. E. et al. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 39, 1267-1276 (2004). (Pubitemid 38569048)
76. Nassif, A. et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114, 1209-1215 (2004). (Pubitemid 39469167)
77. Farrell, J. et al. Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J. Pharmacol. Exp. Ther. 306, 229-237 (2003). (Pubitemid 36734377)
78. Schnyder, B. et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J. Immunol. 164, 6647-6654 (2000). (Pubitemid 30408852)
79. Sanderson, J. P. et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J. Immunol. 178, 5533-5542 (2007). (Pubitemid 46674348)
80. Lavergne, S. N. et al. Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis. Chem. Res. Toxicol. 23, 1009-1011 (2010).
81. Park, B. K., Pirmohamed, M. & Kitteringham, N. R. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11, 969-988 (1998). (Pubitemid 28447286)
82. Kitteringham, N. R., Kenna, J. G. & Park, B. K. Detection of autoantibodies directed against human hepatic endoplasmic-reticulum in sera from patients with halothane-associated hepatitis. Br. J. Clin. Pharmacol. 40, 379-386 (1995).
83. Cheng, L., You, Q., Yin, H., Holt, M. P. & Ju, C. Involvement of natural killer T cells in halothane-induced liver injury in mice. Biochem. Pharmacol. 80, 255-261 (2010).
84. You, Q., Cheng, L. & Ju, C. Generation of T cell responses targeting the reactive metabolite of halothane in mice. Toxicol. Lett. 194, 79-85 (2010).
85. Maria, V. A. & Victorino, R. M. Immunological investigation in hepatic drug reactions. Clin. Exp. Allergy 28 (Suppl. 4), 71-77 (1998).
86. Aithal, G. P. et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39, 1430-1440 (2004). (Pubitemid 38569066)
87. Daly, A. K. et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132, 272-281 (2007). (Pubitemid 46108755)
88. Hanzlik, R. P., Fang, J. & Koen, Y. M. Filling and mining the reactive metabolite target protein database. Chem. Biol. Interact. 179, 38-44 (2009).
89. Nakamura, Y. et al. Redox regulation of glutathione S-transferase induction by benzyl isothiocyanate: correlation of enzyme induction with the formation of reactive oxygen intermediates. Cancer Res. 60, 219-225 (2000). (Pubitemid 30070737)